PL EN


2019 | 1 | 79-82
Article title

Infliximab in therapy of inflammatory bowels diseases

Content
Title variants
Languages of publication
EN
Abstracts
EN
Introduction. Infliximab is a monoclonal antibody that acts against tumor necrosis factor TNF-α. The drug is used in the treatment of autoimmune diseases. Aim. This article reviewed the efficacy and safety of infliximab for the treatment in severe ulcerative colitis. This review included studies that evaluated the clinical use of infliximab. Material and methods. This meta-analysis was performed according to systematic literature search of three major bibliographic databases (Scopus, PubMed, and Cochran). Results. Infliximab has been approved by the US Food and Drug Administration (FDA) as a medicine to treat Leśniowski and Crohn’s disease, ulcerative colitis, psoriasis, psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis. However, further trials are required to compare other parameters of efficacy such as the clinical response with infliximab. Conclusion. In patients suffering from Crohn’s disease or ulcerative colitis under infliximab maintenance therapy, sustained good trough levels are associated with: better response and remission rates, more mucosal healing and less loss of response.
Keywords
Year
Issue
1
Pages
79-82
Physical description
Contributors
author
  • Clinical Department of Pathomorphology, Clinical Hospital No. 2, Rzeszów, Poland
  • Department of Biochemistry and General Chemistry, Faculty of Medicine, University of Rzeszów, Rzeszów, Poland
  • Department of Biochemistry and General Chemistry, Faculty of Medicine, University of Rzeszów, Rzeszów, Poland
author
  • Department of Gastroenterology, Faculty of Medicine, University of Rzeszów, Rzeszów, Poland
  • Department of Photomedicine and Physical Chemistry, Faculty of Medicine, University of Rzeszów, Rzeszów, Poland
References
Document Type
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.mhp-f5a05203-bdf3-43a1-b9ba-70d5339a0bba
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.